HSDT vs. BIOL, STSS, IONM, AFIB, BRSH, SDCCQ, GMVDF, VRAYQ, AHPI, and NMRD
Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include BIOLASE (BIOL), Sharps Technology (STSS), Assure (IONM), Acutus Medical (AFIB), Bruush Oral Care (BRSH), SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), ViewRay (VRAYQ), Allied Healthcare Products (AHPI), and Nemaura Medical (NMRD). These companies are all part of the "medical equipment" industry.
Helius Medical Technologies vs. Its Competitors
Helius Medical Technologies (NASDAQ:HSDT) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.
Helius Medical Technologies has higher earnings, but lower revenue than BIOLASE. Helius Medical Technologies is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.
Helius Medical Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
BIOLASE has a net margin of -41.65% compared to Helius Medical Technologies' net margin of -3,010.14%. Helius Medical Technologies' return on equity of -418.82% beat BIOLASE's return on equity.
In the previous week, Helius Medical Technologies had 6 more articles in the media than BIOLASE. MarketBeat recorded 6 mentions for Helius Medical Technologies and 0 mentions for BIOLASE. Helius Medical Technologies' average media sentiment score of 0.16 beat BIOLASE's score of 0.00 indicating that Helius Medical Technologies is being referred to more favorably in the media.
BIOLASE has a consensus price target of $1.20, indicating a potential upside of 11,167.61%. Given BIOLASE's stronger consensus rating and higher probable upside, analysts clearly believe BIOLASE is more favorable than Helius Medical Technologies.
18.6% of Helius Medical Technologies shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 17.9% of Helius Medical Technologies shares are held by company insiders. Comparatively, 0.3% of BIOLASE shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Helius Medical Technologies and BIOLASE tied by winning 8 of the 16 factors compared between the two stocks.
Get Helius Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helius Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:HSDT) was last updated on 7/1/2025 by MarketBeat.com Staff
